StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc.

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$682.65−14.35 (-2.06%)

Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%

Thermo Fisher Scientific Total MAUDE MDR Device Adverse Event Reports for by Quarter

Total MAUDE MDR Device Adverse Event Reports for Thermo Fisher (openFDA MAUDE)

Thermo Fisher Scientific Total MAUDE MDR Device Adverse Event Reports for: 15 in Q3 2026, up 25.0% from a year earlier.

Latest, Q3 2026
15
Period ended Sep 30, 2026
Change on a year earlier
+25.0%
12 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
1
openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries

Where the Q3 2026 figure comes from

Source: openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗

Reported in U.S. FDA openFDA MAUDE Adverse Event API.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal MAUDE MDR Device Adverse Event Reports for Thermo Fisher (openFDA MAUDE)Year on yearSource
Q3 2026Sep 30, 202615+25.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q2 2026Jun 30, 202613-18.7%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q1 2026Mar 31, 202618-40.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q4 2025Dec 31, 202518-45.5%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q3 2025Sep 30, 202512+33.3%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q2 2025Jun 30, 202516-15.8%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q1 2025Mar 31, 202530+11.1%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q4 2024Dec 31, 202433+135.7%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q3 2024Sep 30, 20249-52.6%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q2 2024Jun 30, 202419+171.4%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q1 2024Mar 31, 202427+200.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q4 2023Dec 31, 2023140.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q3 2023Sep 30, 202319+58.3%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q2 2023Jun 30, 20237-75.9%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q1 2023Mar 31, 20239-10.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗
Q4 2022Dec 31, 2022140.0%openFDA MAUDE Adverse Event Reports (Total) — Thermo Fisher & Subsidiaries ↗

Cite this data

StockData. (2026). Thermo Fisher Scientific Total MAUDE MDR Device Adverse Event Reports for, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/fda-maude-total

See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.